Section Items

Clarification
The comments on this page are some of the thoughts that I had when considering this company and not a recommendation to take an action or to refrain from taking an action.

As you know we have no information about your circumstances, understanding of your investment goals or the level of risk that is acceptable to you. So it would be completely unreasonable to read these commentaries as recommendations.
Is This Just Pump And Dump?
I may or may not own the shares which have commentaries on this site.

Commentaries tend to be created when I look at a share and decide if it is one that I want to buy either now or when I next have an unallocated pot.
Financials
As companies often report numbers in slightly different ways there are a number of entries to cover this and as these are rough notes there will usually be empty items.

The debt columns are shown as positive values if there is any debt, all other negative values are shown within parenthesis and without a sign.

Commentary On Woodford Patient Capital Trust PLC

Title: Woodford Patient Capital Trust – Is It Now A Buy?
Company: WPCT - Woodford Patient Capital Trust PLC
Share Price Then: 39p
Author: Ian Smith
Date: Fri 25 Oct 2019
Comments: With a new manager, Schroders, is WCPT now a buy?

Fees are now known to be 1% a year on the first £600 million of assets and 0.8% on assets above this as well as a fee of 15% of any excess returns above a NAV per share of 77p.

So I suspect not.

Towards the end of October the NAV of the trust was just under 63p, so even at 40p there seems to be a big difference between share price and NAV which means that either the world is missing a bargain or the NAV is optimistic.

I’m betting on the optimistic NAV side.

Schroders have no skin in the current valuations and it seems inevitable that one of the first things that they will do is look at each investment and put their own valuation on it.

This could easily see massive write downs on NAV to levels a lot below the current share price.

There are so many valuations based on funds raised rather than revenue earned that I wouldn’t be surprised to see the valuation drop as low as 2p-10p per share.

Rutherford Cancer Centre (Proton Partners) looks like a very promising business and I can see the demand, seeing the revenue and profit though is harder.

Benevolent AI could possibly brilliant but again revenue, reported at a few million dollars against a valuation of $1bn

Autolus, any income at all?

Industrial Heat well…either Woodford saw something that nobody else is seeing even now or it seems that he got fooled! Muon-catalyzed fusion is real science but nobody seems to have an idea on now to make it a useful product, NASA has put some money into LENR but it was a tiny amount to them and why shouldn’t they?

It would be easy to be cautious and say that these four businesses are actually close to worthless to the early stage investors such as Woodford.

This then leaves the question of the loan, the £113m from Northern Trust, will Schroders sell assets to repay it or try and keep it open, incur interest and hope that this is offset by real growth or income from the investments?

So instead of the very low value I suggested above is WPCT actually worthless, will it just slowly eat up its own value paying fees and interest?
Financials:
ItemCurrent PeriodPrevious Period
YearN/A N/A
Period12 Months12 Months
Revenue
Earnings
Adjusted Earnings
EBITDA
Adjusted EBITDA
Statutory Profit
Adjusted Profit
Total Debt
Net Debt
Read Count: 252

Commentary History

Date Ticker Title
Fri 25 Oct 2019WPCTWoodford Patient Capital Trust – Is It Now A Buy?